Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
Completed · Phase 2
Conditions studied: Kidney Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with irinotecan works in treating patients with metastatic kidney cancer.
Key facts
- Study ID
- NCT00401128
- Run by
- The Cleveland Clinic
- People needed
- 9
- Starts
- 2004-05-01
- Expected to finish
- 2007-02-01
- Last updated by the study team
- 2017-04-20
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.